1. SPANISH HEAD AND NECK CANCER COOPERATIVE GROUP (TTCC)

2. February 2000 1 st International Head & Neck Symposium 2001 Cooperative Group with 15 members National Symposiums TTCC 2005_Barcelona 2007_Salamanca 2009_Zaragoza 2011_Valencia

3. ACTIVITIES TRAINING DISCLOSURE PREVENTION DIAGNOSIS TREATMENT TRAINING DISCLOSURE PREVENTION DIAGNOSIS TREATMENT

4. Clinical Trials Closed: 5 Opened: 3 Approved by the CEC: 2 Over 1.000 patients PREVENTION, PRESERVATION, LOCOREGIONAL AND METASTASIC

5. QTI / NEW MEDICAMENTS MOLECULAR TARGETS SURGERY RDT QTRDT RT-E RDT QTRDT RT-E SUPPORT BASIC AND TRASLACIONAL INVESTIGATION

6. A randomized phase II, multicenter trial of induction with Cisplatin/ Docetaxel verus Cisplatin/5-fluorouracil for patients with locally advanced head and neck carcinoma. February 2000 and July 2001, 84 patients TAX-ES-202. Published in Eur J Cancer. 2005 Jun;41(9):1254-60. A randomized, multicenter phase III trial comparing induction chemotherapy with Cisplatin/5-FU (PF) or Docetaxel/Cisplatin/5-FU (TPF) plus chemotherapy (CRT) versus CRT alone as fisrt-line treatment of unresectable locally advanced head and neck cancer. XRP6976F / 2503. COMUNICACIÓN ORAL ASCO 2006. Phase II study of combination Cetuximab and weekly Paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck ERBITAX. ASCO 2007. Pending of publication Phase II study of Capecitabine as palliative treatment for patients with squamous head and neck cancer with locoregional and/or metastatic relapse after previous Platinium-based treatment. XEL-CYC-TTCC. POSTER ASCO 2009. Pending of publication A single arm, multicenter, phase II trial to evaluate the combination of cetuximab plus taxotere (T), cisplatin (P) and 5- fluorouracil (F) (TPF) as induction chemotherapy in patients (pts) with unresectable squamous cell carcinoma of the head and neck. NEO-TPFE-TTCC. Póster discusión ASCO 2009. Preliminar results A randomized, multicenter phase III trial comparing induction chemotherapy with Cisplatin/5-FU (PF) or Docetaxel/Cisplatin/5-FU (TPF) plus chemotherapy (CRT) versus CRT alone as fisrt-line treatment of unresectable locally advanced head and neck cancer. XRP6976F / 2503. COMUNICACIÓN ORAL ASCO 2009. Pending of publication

7. Open Studies An Open Label Randomized, Multi-Centre Phase III Trial of TPF Chemotherapy Plus Concomitant Treatment With Cisplatin and Conventional Radiotherapy Versus TPF Chemotherapy Plus Concomitant Cetuximab and Conventional Radiotherapy in Locally Advanced, Un-resectable Head and Neck Cancer. TTCC-2007-01 (ClinicalTrials.gov Identifier: NCT00716391) A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF Chemotherapy. TTCC-2007-02 ( ClinicalTrials.gov Identifier: NCT00765011) An Open Label Randomized, Phase III Trial With Erlotinib (Tarceva®) as Maintenance Treatment in Patients With Operated Squamous Cell Carcinoma of the Head and Neck and treated with Chemo-radiotherapy or Radiotherapy with Curative Purposes. ML20294 (Nº EudraCT: 2006-001845-33)

8. PANITUMUMAB IN METASTASICS IN LOCALLY ADVANCED LAPATINIB THYROIDS CANCER NASOPHARYNGEAL CANCER